TL;DR: The Centers for Medicare & Medicaid Services retired NCD 220.6.5 (FDG PET for Lymphoma) and replaced it with section 220.6.17. If your team still references 220.6.5 in your billing guidelines or payer policy library, update it now — the old section is gone.

CMS formally retired NCD 220.6.5 from the National Coverage Determination Manual, effective April 10, 2023, with the revision published January 9, 2026 in the NCD 300 CMS system. The active FDG-PET lymphoma coverage policy now lives entirely under section 220.6.17. The policy does not list specific CPT or HCPCS codes in the retired section itself — those are governed by the replacement section 220.6.17 and the parent PET scan NCD at §220.6.


Quick-Reference Table

Field Detail
Payer CMS
Policy FDG PET for Lymphoma (RETIRED) — Replaced by NCD 220.6.17
Policy Code NCD 300 (section 220.6.5)
Change Type Modified (retirement/redirect)
Effective Date April 10, 2023 (retirement); revision published January 9, 2026
Impact Level Medium — administrative risk if teams still cite the retired section
Specialties Affected Oncology, Nuclear Medicine, Radiology, Hematology
Key Action Update all internal billing guidelines and payer policy references from NCD 220.6.5 to NCD 220.6.17 immediately

CMS FDG PET Lymphoma Coverage Criteria and Medical Necessity Requirements 2026

Here's the real situation: CMS retired section 220.6.5 governing FDG PET for lymphoma back on April 10, 2023. The January 9, 2026 revision simply confirms that removal and cross-references the replacement.

The active CMS FDG PET lymphoma coverage policy is now section 220.6.17. That is where you find current medical necessity criteria, coverage indications, and billing guidelines for FDG-PET in lymphoma patients. If your team is still pulling up 220.6.5 to answer a prior authorization question or respond to a claim denial, you are working from a dead document.

The parent NCD at §220.6 governs PET scans broadly for Medicare. Section 220.6.17 is the lymphoma-specific child policy. Both are active. Section 220.6.5 is not.

The retired section itself contains no medical necessity criteria, no coverage indications, and no applicable codes. It exists in the NCD Manual only as a tombstone — a notice that the content moved. Any medical necessity determination for FDG PET in lymphoma billing must reference 220.6.17, not 220.6.5.


Coverage Indications at a Glance

Because section 220.6.5 is retired and contains no substantive coverage criteria, the table below reflects what this policy does and does not address. For full indication-level coverage details, you must reference NCD 220.6.17 directly.

Indication Status Under 220.6.5 Relevant Codes Notes
FDG PET for Lymphoma (all indications) Retired — no active coverage status See NCD 220.6.17 Coverage policy relocated to section 220.6.17, effective April 3, 2009
Any lymphoma-related PET billing Not governed here See §220.6 (parent NCD) Bill under active policy section only

The policy does not list specific CPT or HCPCS codes in this retired section. Do not use 220.6.5 as a billing authority for any claim.


This policy is now in effect (since 2026-03-12). Verify your claims match the updated criteria above.

CMS FDG PET Lymphoma Billing Guidelines and Action Items 2026

This retirement is not a new development clinically — coverage criteria did not change. The risk is entirely administrative. Billing teams that reference outdated policy sections in their documentation, prior authorization requests, or appeal letters create unnecessary exposure.

Here is what to do:

#Action Item
1

Audit your internal policy library today. Search your billing guidelines, payer policy binders, and any internal reference documents for "220.6.5" or "NCD 220.6.5." Replace every instance with a reference to NCD 220.6.17.

2

Update your prior authorization templates. If your team submits prior auth requests for FDG PET in lymphoma patients and cites a specific NCD section, confirm the citation reads 220.6.17 — not 220.6.5. Citing a retired section in a prior auth request is a simple fix that can become a costly delay if a reviewer flags it.

3

Check your appeal letter templates. Claim denial appeals that cite NCD 220.6.5 as the coverage authority are citing a section CMS removed. Update those templates to reference 220.6.17 and §220.6.

+ 3 more action items

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

If your organization has a high volume of oncology PET billing and you're not sure which section your templates reference, loop in your compliance officer before submitting another batch.


Sample Version Diff Line-by-line changes
Previous VersionCurrent Version
Coverage is considered experimental and investigational for all indicationsCoverage is considered medically necessary when specific criteria are met
Prior authorization is not requiredPrior authorization is required for initial treatment
Documentation must include clinical historyDocumentation must include clinical history
+ 1 more action items

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

CPT, HCPCS, and ICD-10 Codes for FDG PET Lymphoma Under NCD 300

The retired section 220.6.5 does not list any CPT, HCPCS, or ICD-10 codes. CMS explicitly removed all substantive content from this section when it was retired.

No Codes Listed in This Policy Section

Code Type Description
No codes specified in NCD 220.6.5 (retired). See NCD 220.6.17 for applicable codes.

The FDG PET lymphoma billing codes — including the relevant PET scan HCPCS codes — are governed by NCD 220.6.17 and the parent PET scan NCD at §220.6. Do not reference this retired section as a coding authority.


Why This Matters More Than It Looks

A retired policy section sounds like housekeeping. In most cases, it is. But FDG PET for lymphoma billing has real financial exposure — PET scans are high-cost procedures, and claim denials based on incorrect policy citations are avoidable.

The gap between when CMS retired 220.6.5 (April 2009, formalized in April 2023) and today means some teams have been working with outdated references for years without a denial to trigger a correction. This January 2026 revision is your prompt to fix it.

The real issue here is not coverage — medical necessity criteria for FDG PET in lymphoma did not change with this retirement. The issue is documentation integrity. When your prior auth, your appeal letter, and your billing guidelines all cite a section that no longer exists, you are one sharp-eyed reviewer away from a delay or denial that has nothing to do with whether the scan was clinically appropriate.


Get the Full Picture

Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.

🔍 Search by any code 🔔 Real-time alerts 📊 Line-by-line diffs ⏰ Deadline tracking
Get Full Access → $99/mo · 14-day money-back guarantee